摘要
目的探讨DSA引导下经皮穿刺分别注射高渗葡萄糖及无水乙醇置管引流治疗巨大肝囊肿的3、6和12个月疗效比较。方法回顾性选择临床资料完整的73例单纯性肝囊肿患者行对照研究,其中27例行高渗葡萄糖硬化治疗(A组),46例行无水乙醇硬化治疗(B组)为对照组。囊肿直径8.3～15.8 cm。所有病灶均在DSA引导下进行肝囊肿穿刺抽液,置管引流硬化治疗;术后3、6和12个月比较其疗效。结果 73例患者全部顺利完成治疗,肝囊肿穿刺成功率100%,两组3、6和12个月疗效差异无显著性,P值分别为0.526、0.713、0.613(P均>0.05)。结论 DSA引导下经皮穿刺置管引流后注射高渗葡萄糖或无水乙醇硬化治疗肝囊肿在3、6和12个月疗效上无明显差异,其中,高渗葡萄糖硬化术后不适症状少,更适合体弱的中老年患者。
Objective To compare the 3-month, 6-month and 12-month therapeutic efficacy of DSA- guided pereutaneous injection of hypertonic glucose or ethanol combined with catheter directed drainage for the treatment of giant hepatic cysts. Methods A total of seventy-three eases of single hepatic cysts with complete clinical data were retrospectively selected. Injection of hypertonie glucose was employed for sclerotherapy in 27 patients （group A）, while sclerotherapy with ethanol injection was adopted in 46 patients （group B）. Cyst diameters ranged from 8.3 cm to 15.8 cm. Under DSA guidance, puncturing injection of sclerotic agents and catheter directed drainage and aspiration were carried out for all lesions. The therapeutic efficacy at 3, 6 and 12 months were evaluated and the results were compared between the two groups. Results The therapeutic procedure was successfully accomplished in all 73 cases. The puncturing success rate of the hepatic cysts was 100%. No significant difference in the 3-month, 6-month and 12-month therapeutic efficacy existed between the two groups, and the P values were 0.526, 0.713 and 0.613, respectively （P 〉 0.05）. Conclusion In treating giant hepatic cysts with sclerotherapy, the 3-month, 6-month and 12-month therapeutic efficacy of using hypertonic glucose as sclerotic agent are not significantly different from those of using ethanol as sclerotic agent. As the use of hypertonic glucose carries less disagreeable feeling it is more suitable for the debilitated and aged patients.
出处
《介入放射学杂志》
CSCD
北大核心
2012年第2期127-130,共4页
Journal of Interventional Radiology
关键词
囊肿
DSA
高渗葡萄糖
无水乙醇
硬化治疗
cyst
digital subtraction angiography
hypertonic glucose
ethanol
sclerotherapy
